Comparative molecular field analysis of substrates for an aryl sulfotransferase based on catalytic mechanism and protein homology modeling

Journal of Medicinal Chemistry

Volumn 45, Issue 25, 2002, Pages 5514-5522

  Sharma, Vyas ^a   Duffel, Michael W ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYL SULFOTRANSFERASE; ARYL SULFOTRANSFERASE IV; HISTIDINE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME CONFORMATION; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME STRUCTURE; METHODOLOGY; MODEL; MOLECULE; PREDICTION; PROTEIN EXPRESSION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGRESSION ANALYSIS; SEQUENCE HOMOLOGY; VALIDATION PROCESS;

ANIMALS; CATALYSIS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY; SULFOTRANSFERASES;

EID: 0037028020     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010481c     Document Type: Article

References (61)

1. Mulder, G. J.; Jakoby, W. B. Sulfation. Conjugation reactions in drug metabolism; Taylor & Francis: New York, 1990; pp 107-161.
2. Weinshilboum, R.; Otterness, D. Sulfotransferase enzymes. Handbook of Experimental Pharmacology; Springer-Verlag: Berlin, 1994; pp 45-78.
3. Duffel, M. W. Sulfotransferases. In Volume 3. Biotransformation (Guengerich, F. P., vol. Ed.). In Comprehensive Toxicology; Sipes, I. G., McQueen, C. A., Gandolfi, A. J., Eds.; Elsevier: Oxford, 1997; pp 365-383.
4. Duffel, M. W.; Marshall, A. D.; McPhie, P.; Sharma, V.; Jakoby, W. B. Enzymatic aspects of the phenol (aryl) sulfotransferases. Drug Metab. Rev. 2001, 33, 369-395.
5. Weinshilboum, R. M.; Otterness, D. M.; Aksoy, I. A.; Wood, T. C.; Her, C.; Raftogianis, R. B. Sulfation and sulfotransferases 1: Sulfotransferase molecular biology: cDNAs and genes. FASEB J. 1997, 11, 3-14.
6. Nagata, K.; Yamazoe, Y. Pharmacogenetics of sulfotransferase. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 159-176.
7. Miller, J. A.; Surh, Y.-J. Sulfonation in chemical carcinogenesis. Handbook of Experimental Pharmacology; Springer-Verlag: Berlin, 1994; pp 429-457.
8. Beland, F. A.; Kadlubar, F. F. Metabolic activation and DNA adducts of aromatic amines and nitroaromatic hydrocarbons. Handbook of Experimental Pharmacology, Vol. 94/I; Springer-Verlag: Heidelberg, 1990; pp 267-325.
9. Glatt, H. R. An overview ofbioactivation of chemical carcinogens. Biochem. Soc. Trans. 2000, 28, 1-6.
10. Glatt, H.; Engelke, C. E.; Pabel, U.; Teubner, W.; Jones, A. L.; Coughtrie, M. W.; Andrae, U.; Falany, C. N.; Meinl, W. Sulfo-transferases: Genetics and role in toxicology. Toxicol. Lett. 2000, 112-113, 341-8.
11. Sekura, R. D.; Jakoby, W. B. Aryl sulfotransferase IV from rat liver. Arch Biochem. Biophys. 1981, 211, 352-359.
12. Lewis, A. J.; Kelly, M. M.; Walle, U. K.; Eaton, E. A.; Falany, C. N.; Walle, T. Improved bacterial expression of the human P form phenolsulfotransferase: Applications to drug metabolism. Drug Metab. Dispos. 1996, 24, 1180-1185.
13. Walle, T.; Walle, U. K. Stereoselective sulfate conjugation of racemic 4-hydroxypropranolol by human and rat liver cytosol. Drug Metab. Dispos. 1991, 19, 448-453.
14. Johnson, G. A.; Barshun, K. J.; McCall, J. M. Sulfation of minoxidil by liver sulfotransferase. Biochem. Pharmacol. 1982, 31, 2949-2954.
15. Singer, S. S. The same enzymes catalyze sulfation of minoxidil, minoxidil analogues and catecholamines. Chem. Biol. Interact. 1994, 92, 33-45.
16. Hartman, A. P.; Wilson, A. A.; Wilson, H. M.; Aberg, G.; Falany, C. N.; Walle, T. Enantioselective sulfation of b2-receptor agonists by the human intestine and the recombinant M-form phenol-sulfotransferase. Chirality 1998, 10, 800-803.
17. Duffel, M. W. Molecular specificity of aryl sulfotransferase IV (tyrosine-ester sulfotransferase) for xenobiotic substrates and inhibitors. Chem. Biol. Interact. 1994, 92, 3-14.
18. Duffel, M. W.; Modi, R. B.; King, R. Interactions of a primary N-hydroxy arylamine with rat hepatic aryl sulfotransferase IV. Drug Metab. Dispos. 1992, 20, 339-342.
19. King, R. S.; Sharma, V.; Pedersen, L. C.; Kakuta, Y.; Negishi, M.; Duffel, M. W. Structure-function modeling of the interactions of N-alkyl-N-hydroxyanilines with rat hepatic aryl sulfotransferase IV. Chem. Res. Toxicol. 2000, 13, 1251-1258.
20. King, R. S.; Teitel, C. H.; Kadlubar, F. F. In vitro bioactivation of N-hydroxy-2-amino-α-carboline. Carcinogenesis 2000, 21, 1347-1354.
21. Meerman, J. H.; Ringer, D. P.; Coughtrie, M. W.; Bamforth, K. J.; Gilissen, R. A. Sulfation of carcinogenic aromatic hydroxylamines and hydroxamic acids by rat and human sulfotransferases: Substrate specificity, developmental aspects and sex differences. Chem. Biol. Interact. 1994, 92, 321-328.
22. Mangold, J. B.; Spina, A.; McCann, D. J. Sulfation of mono- and diaryl oximes by aryl sulfotransferase isozymes. Biochim. Biophys. Acta 1989, 991, 453-458.
23. Mangold, J. B.; McCann, D. J.; Spina, A. Aryl sulfotransferase-IV-catalyzed sulfation of aryl oximes: Steric and substituent effects. Biochim. Biophys. Acta 1993, 1163, 217-222.
24. Rao, S. I.; Duffel, M. W. Benzylic alcohols as stereospecific substrates and inhibitors for aryl sulfotransferase. Chirality 1991, 3, 104-111.
25. Sodum, R. S.; Sohn, O. S.; Nie, G.; Fiala, E. S. Activation of the liver carcinogen 2-nitropropane by aryl sulfotransferase. Chem. Res. Toxicol. 1994, 7, 344-351.
26. Borchert, P.; Miller, J. A.; Miller, E. C.; Shires, T. K. 1′-Hydroxysafrole, a proximate carcinogenic metabolite of safrole in the rat and mouse. Cancer Res. 1973, 33, 590-600.
27. Miller, E. C.; Swanson, A. B.; Phillips, D. H.; Fletcher, T. L.; Liem, A.; Miller, J. A. Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer Res. 1983, 43, 1124-1134.
28. Kato, R.; Yamazoe, Y. Metabolic activation of N-hydroxylated metabolites of carcinogenic and mutagenic arylamines and arylamides by esterification. Drug Metab. Rev. 1994, 26, 413-429.
29. Fiala, E. S.; Sodum, R. S.; Hussain, N. S.; Rivenson, A.; Dolan, L. Secondary nitroalkanes: Induction of DNA repair in rat hepatocytes, activation by aryl sulfotransferase and hepatocarcinogenicity of 2-nitrobutane and 3-nitropentane in male F344 rats. Toxicology 1995, 99, 89-97.
30. Yoshinari, K.; Petrotchenko, E. V.; Pedersen, L. C.; Negishi, M. Crystal structure-based studies of cytosolic sulfotransferase. J. Biochem. Mol. Toxicol. 2001, 15, 67-75.
31. Negishi, M.; Pedersen, L. G.; Petrotchenko, E.; Shevtsov, S.; Gorokhov, A.; Kakuta, Y.; Pedersen, L. C. Structure and function of sulfotransferases. Arch. Biochem. Biophys. 2001, 390, 149-157.
32. Kakuta, Y.; Pedersen, L. G.; Carter, C. W.; Negishi, M.; Pedersen, L. C. Crystal structure of estrogen sulphotransferase. Nat. Struct. Biol. 1997, 4, 904-908.
33. Dajani, R.; Cleasby, A.; Neu, M.; Wonacott, A. J.; Jhoti, H.; Hood, A. M.; Modi, S.; Hersey, A.; Taskinen, J.; Cooke, R. M.; Manchee, G. R.; Coughtrie, M. W. X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. Molecular modeling and quantitative structure-activity relationship analysis demonstrate a molecular basis for sulfotransferase substrate specificity. J. Biol. Chem. 1999, 274, 37862-37868.
34. Bidwell, L. M.; McManus, M. E.; Gaedigk, A.; Kakuta, Y.; Negishi, M.; Pedersen, L.; Martin, J. L. Crystal structure of human catecholamine sulfotransferase. J. Mol. Biol. 1999, 293, 521-530.
35. Kakuta, Y.; Sueyoshi, T.; Negishi, M.; Pedersen, L. C. Crystal structure of the sulfotransferase domain of human heparan sulfate N-deacetylase/N-sulfotransferase 1. J. Biol. Chem. 1999, 274, 10673-10676.
36. Pedersen, L. C.; Petrotchenko, E. V.; Negishi, M. Crystal structure of SULT2A3, human hydroxysteroid sulfotransferase. FEBS Lett. 2000, 475, 61-64.
37. Petrotchenko, E. V.; Pedersen, L. C.; Borchers, C. H.; Tomer, K. B.; Negishi, M. The dimerization motif of cytosolic sulfotransferases. FEBS Lett. 2001, 490, 39-43.
38. Kakuta, Y.; Petrotchenko, E. V.; Pedersen, L. C.; Negishi, M. The sulfuryl transfer mechanism. Crystal structure of a vanadate complex of estrogen sulfotransferase and mutational analysis. J. Biol. Chem. 1998, 273, 27325-27330.
39. Duffel, M. W.; Jakoby, W. B. On the mechanism of aryl sulfotransferase. J. Biol. Chem. 1981, 256, 11123-11127.
40. Marshall, A. D.; McPhie, P.; Jakoby, W. B. Redox control of aryl sulfotransferase specificity. Arch. Biochem. Biophys. 2000, 382, 95-104.
41. King, R. S.; Duffel, M. W. Oxidation-dependent inactivation of aryl sulfotransferase IV by primary N-hydroxy arylamines during in vitro assays. Carcinogenesis 1997, 18, 843-849.
42. Chen, G.; Banoglu, E.; Duffel, M. W. Influence of substrate structure on the catalytic efficiency of hydroxysteroid sulfotransferase STa in the sulfation of alcohols. Chem. Res. Toxicol. 1996, 9, 67-74.
43. Banoglu, E.; Duffel, M. W. Studies on the interactions of chiral secondary alcohols with rat hydroxysteroid sulfotransferase STa. Drug Metab. Dispos. 1997, 25, 1304-1310.
44. Chen, X.; Yang, Y. S.; Zheng, Y.; Martin, B. M.; Duffel, M. W.; Jakoby, W. B. Tyrosine-ester sulfotransferase from rat liver: Bacterial expression and identification. Protein Expr. Purif. 1992, 3, 421-426.
45. Duffel, M. W.; Binder, T. P.; Rao, S. I. Assay of purified aryl sulfotransferase suitable for reactions yielding unstable sulfuric acid esters. Anal. Biochem. 1989, 183, 320-324.
46. Brunger, A. T.; Kuriyan, J.; Karplus, M. Crystallographic R-factor refinement by molecular dynamics. Science 1987, 235, 458-460.
47. Zheng, Y.; Bergold, A.; Duffel, M. Affinity labeling of aryl sulfotransferase IV: Identification of a peptide sequence at the binding site for 3′-phosphoadenosine-5′-phosphosulfate. J. Biol. Chem. 1994, 269, 30313-30319.
48. Campbell, N. R.; Van Loon, J. A.; Sundaram, R. S.; Ames, M. M.; Hansch, C.; Weinshilboum, R. Human and rat liver phenol sulfotransferase: Structure-activity relationships for phenolic substrates. Mol. Pharmacol. 1987, 32, 813-819.
49. Cramer, R. D. I.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
50. Golbraikh, A.; Bernard, P.; Chretien, J. R. Validation of protein-based alignment in 3D quantitative structure - Activity relationships with CoMFA models. Eur. J. Med. Chem. 2000, 35, 123-136.
51. Jalaie, M.; Erickson, J. A. Homology model directed alignment selection for comparative molecular field analysis: application to photosystem II inhibitors. J. Comput.-Aided Mol. Des. 2000, 14, 181-197.
52. 2. Eur. J. Med. Chem. 2001, 36, 21-30.
53. Cavalli, A.; Greco, G.; Novellino, E.; Recanatini, M. Linking CoMFA and protein homology models of enzyme-inhibitor interactions: An application to nonsteroidal aromatase inhibitors. Bioorg. Med. Chem. 2000, 8, 2771-2780.
54. Bernard, P.; Kireev, D. B.; Chretien, J. R.; Fortier, P.-L.; Coppet, L. Automated docking of 82 N-benzylpiperidine derivatives to mouse acetylcholinesterase and comparative molecular field analysis with "natural" alignment. J. Comput. -Aided Mol. Des. 1999, 13, 355-371.
55. 2. Eur. J. Med. Chem. 2001, 36, 1-19.
56. Cleland, W. W. What limits the rate of an enzyme-catalyzed reaction? Acc. Chem. Res. 1975, 8, 145-151.
57. Northrup, D. B. Rethinking fundamentals of enzyme action. Adv. Enzymol. Relat. Areas Mol. Biol. 1999, 73, 25-55.
58. Kraulis, P. J. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Applied Crystallography 1991, 24, 946-950.
59. Merrit, E. A.; Bacon, D. J. Raster3D: Photorealistic molecular graphics. Methods Enzymol 1997, 77, 505-524.
60. Duffel, M. W.; Chen, G.; Sharma, V. Studies on an affinity label for the sulfuryl acceptor binding site in an aryl sulfotransferase. Chem. Biol. Interact. 1998, 109, 81-92.
61. Binder, T. P.; Duffel, M. W. Sulfation of benzylic alcohols catalyzed by aryl sulfotransferase IV. Mol. Pharmacol. 1988, 33, 477-479.